Original Article

You have full text access to this OnlineOpen article

Treatment failure after primary and salvage therapy for prostate cancer†

Likelihood, patterns of care, and outcomes

  1. Piyush K. Agarwal MD1,
  2. Natalia Sadetsky MD, MPH2,
  3. Badrinath R. Konety MD, MBA2,
  4. Martin I. Resnick MD1,
  5. Peter R. Carroll MD2,‡,§,*

Article first published online: 29 NOV 2007

DOI: 10.1002/cncr.23161

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 307–314, 15 January 2008

Additional Information

How to Cite

Agarwal, P. K., Sadetsky, N., Konety, B. R., Resnick, M. I. and Carroll, P. R. (2008), Treatment failure after primary and salvage therapy for prostate cancer. Cancer, 112: 307–314. doi: 10.1002/cncr.23161

Author Information

  1. 1

    Department of Urology, Case Western Reserve University School of Medicine and University Hospitals CASE Medical Center, Cleveland, Ohio

  2. 2

    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco School of Medicine, San Francisco, California

  1. ‡

    Dr. Carroll has acted as a study trial investigator for both the National Cancer Institute and the Department of Defense and received no financial compensation. He has also acted as a member of the Speakers' Bureau for and received honorarium from InfoMedical Communications, and has acted as an investigator for TAP Pharmaceutical Products, for which he received no financial compensation.

  2. §

    Fax: (415) 353-9932

*Department of Urology, University of California at San Francisco, 1600 Divisadero Street, RoomA-610, UCSF Box 1695, San Francisco, CA 94143

  1. †

    See related editorial on pages 225–7, this issue.

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 29 NOV 2007
  3. Manuscript Accepted: 5 JUL 2007
  4. Manuscript Revised: 28 JUN 2007
  5. Manuscript Received: 26 MAR 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (92K)

REFERENCES

  • 1
    Cookson MS. Prostate cancer: screening and early detection. Cancer Control. 2001; 8: 133–140.
  • 2
    Khan MA,Han M,Partin AW,Epstein JI,Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003; 62: 86–91.
  • 3
    Shipley WU,Thames HD,Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA. 1999; 281: 1598–1604.
  • 4
    Grossfeld GD,Li Y,Lubeck DP,Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002; 60( suppl 3A): 57–62.
  • 5
    Mehta SS,Lubeck DP,Sadetsky N,Pasta DJ,Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004; 171: 215–219.
  • 6
    Lubeck DP,Litwin MS,Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48: 773–777.
  • 7
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969–974.
  • 8
    Jhaveri FM,Zippe CD,Klein EA,Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999; 54: 884–890.
  • 9
    Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1642–1645.
  • 10
    Ward JF,Blute ML,Slezak J,Bergstralh EJ,Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003; 170: 1872–1876.
  • 11
    Khuntia D,Reddy CA,Mahadevan A,Klein EA,Kupelian PA. Recurrence-free survival rates after external beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004; 6: 1283–1292.
    Direct Link:
  • 12
    Zagars GK,Pollack A,von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997; 79: 1370–1380.
  • 13
    D'Amico AV,Schultz D,Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000; 284: 1280–1283.
  • 14
    Bolla M,Gonazalez D,Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295–300.
  • 15
    Terai A,Matsui Y,Yoshimura K,Arai Y,Dodo Y. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int. 2005; 96: 1009–1013.
    Direct Link:
  • 16
    Stephenson AJ,Shariat SF,Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004; 291: 1325–1332.
  • 17
    Sanderson KM,Penson DF,Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006; 176: 2025–2031.
  • 18
    Izawa JI,Madsen LT,Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002; 20: 2664–2671.
  • 19
    Horwitz EM,Thames HD,Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005; 173: 797–802.
View Full Article (HTML) Get PDF (92K)